A phase 1/2, Multicenter, Open-Label, Dose-escalation study of AG-221 in subjects with advanced solid tumors, including glioma, and with angioimmunoblastic T-cell lymphoma, that harbor an IDH2 mutation. The gene discussed is IDH2; the disease is central nervous system cancer.